<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="7344768 doi: 10.3390/biology9060141biology-09-00141 : Review Lessons from SARS-CoV-2 Pandemic: Evolution," exact="Disease" post="Dynamics and Future PandeySaurabh1â€ YadavBharat2â€ PandeyArvind3https://orcid.org/0000-0001-6399-9825TripathiTakshashila4https://orcid.org/0000-0003-1728-5500KhawaryMasuma2https://orcid.org/0000-0002-9015-8383KantSashi5*TripathiDeeksha2*[1], saurabhpandey@jamiahamdard.ac.in[2], yadavbharat22@gmail.com2019phdmb05@curaj.ac.in[3], arvindpandey@curaj.ac.in[4],"/>
 <result pre="to summarize the structure, epidemiology, symptoms, statistical status of the" exact="disease" post="status, intervention strategies and deliberates the lessons learnt during"/>
 <result pre="repurposing and vaccine trials are intensified now. Statistical interpretations of" exact="disease" post="dynamics and their projections may help the decision-makers. COVID-19"/>
 <result pre="COVID-19 1.1. SARS-CoV-2: Structure and Similarity to Other Coronaviruses The" exact="infection" post="caused by novel coronavirus, SARS-CoV-2, COVID-19 has turned into"/>
 <result pre="Sarbecovirus) of betacoronaviruses, that includes SARS-CoV-2 and Bat SL-CoV-WIV1, their" exact="primary" post="mode of transmission is through droplet and fecal-oral route"/>
 <result pre="droplet and fecal-oral route [7]. SARS-CoV-2 infects the lung alveolar" exact="epithelial" post="cells using receptor-mediated endocytosis via angiotensin-converting enzyme II (ACE2)"/>
 <result pre="higher infectibility of SARS-CoV-2 could also be due to its" exact="lower" post="fatality rate as compared to SARS and MERS [9]."/>
 <result pre="than 353,334 lives worldwide which is manifold greater than the" exact="total" post="amount of fatalities of SARS and MERS combined [3,11]."/>
 <result pre="is still not clear [3]. It is expected that an" exact="intermediate" post="organism might be involved in this transmission. The mutation"/>
 <result pre="recombination and spillovers and will become the source of future" exact="infections" post="as noted by Dr. Zheng-Li while describing the genetic"/>
 <result pre="recombination events, it might have jumped to new species via" exact="intermediate" post="host like civets (Paguma larvata) or pangolin and then"/>
 <result pre="full convection that civet cat or pangolin are the true" exact="intermediate" post="hosts. The ability to survive in human hosts has"/>
 <result pre="can infect anyone of us, but comorbidities like hypertension, diabetes," exact="respiratory" post="symptoms and kidney disease are significant risk factors and"/>
 <result pre="of us, but comorbidities like hypertension, diabetes, respiratory symptoms and" exact="kidney disease" post="are significant risk factors and may result in severe"/>
 <result pre="us, but comorbidities like hypertension, diabetes, respiratory symptoms and kidney" exact="disease" post="are significant risk factors and may result in severe"/>
 <result pre="WHO situation report on COVID-19 dated 28 May 2020, a" exact="total" post="of 5,593,631 confirmed cases with 353,334 deaths have been"/>
 <result pre="The majority of cases have been reported from European and" exact="American" post="continents, whereas numbers are less in African and Asian"/>
 <result pre="from European and American continents, whereas numbers are less in" exact="African" post="and Asian continents but are increasing rapidly. Globally, cases"/>
 <result pre="increasing rapidly. Globally, cases are doubling every 4â€&quot;5 days [11,25]." exact="African" post="and Asian nations are at higher risk due to"/>
 <result pre="in quantity of cases and deaths, although it has a" exact="lower" post="fatality rate than the latter two [3,10,11]. SARS-CoV-2 has"/>
 <result pre="of SARS-CoV-2 can be attributed to its ability to remain" exact="infectious" post="outside the human body for a long duration of"/>
 <result pre="chances of its spread due to asymptomatic carriers of the" exact="disease" post="present in a population [5,9,11,27,28,29,30]. A Chinese research group"/>
 <result pre="always there [9]. Lockdown employed by China to mitigate the" exact="disease" post="has shown positive results in decreasing the growth rate"/>
 <result pre="shown in 87% of cases in the Chinese Center for" exact="Disease" post="Control and Prevention Report referred by Zunyou Wu, and"/>
 <result pre="Control and Prevention Report referred by Zunyou Wu, and also" exact="infections" post="in males are higher [9,10,32]. SARS-CoV-2 may also affect"/>
 <result pre="out of 182 patients who had completely recovered from the" exact="infection" post="and were discharged from hospital were found to be"/>
 <result pre="China reported that cats and ferrets were susceptible to SARS-CoV-2" exact="infection" post="whereas dogs, pigs, chickens and ducks were not permissive"/>
 <result pre="whereas dogs, pigs, chickens and ducks were not permissive to" exact="infection" post="[36]. The World Organization for Animal Health has reported"/>
 <result pre="[36]. The World Organization for Animal Health has reported SARS-CoV-2" exact="infection" post="in farmed minks, dogs, golden Syrian hamsters, cynomolgus and"/>
 <result pre="reports about their epidemiological role in the spread of the" exact="disease" post="among humans [37], these developments now raise questions over"/>
 <result pre="disease among humans [37], these developments now raise questions over" exact="infective" post="capacity of the virus and the probable role of"/>
 <result pre="world. Up until 28th May 2020, a whopping 5,593,631 corona" exact="infection" post="cases are reported. Among them, 95% of cases are"/>
 <result pre="China and Saudi Arabia) are contributing to 80% of the" exact="total" post="number of cases in the world. Around the globe,"/>
 <result pre="UK, Italy, France, Germany, India, Turkey, Iran and Peru) to" exact="total" post="deaths due to corona infection is nearly 80%. Only"/>
 <result pre="Turkey, Iran and Peru) to total deaths due to corona" exact="infection" post="is nearly 80%. Only seven of the above countries"/>
 <result pre="of the overall deaths in the world due to corona" exact="infection" post="[39]. The distribution of deaths, recovery and active cases"/>
 <result pre="rate of different gender is not known. The rate of" exact="infection" post="in different countries per 100,000 is similar on the"/>
 <result pre="for the age group greater than 50, the number of" exact="infection" post="and death per 100,000 population is very high. In"/>
 <result pre="is very high. In China, the ratio of male and" exact="female" post="death in confirmed cases is 17:10. In India, the"/>
 <result pre="21 years to 60 years contributing to 75% of the" exact="total" post="number of infected cases [41]. The daily growth rate"/>
 <result pre="a number of common symptoms, fever, dry cough, dyspnoea and" exact="bilateral" post="ground-glass opacities in the lungs [42]. Discomfort in breathing"/>
 <result pre="reported among the patients. Less common symptoms are headache, fatigue," exact="chest" post="tightness and diarrhea [9,24]. Previously, diarrhea was reported in"/>
 <result pre="patients. Less common symptoms are headache, fatigue, chest tightness and" exact="diarrhea" post="[9,24]. Previously, diarrhea was reported in patients suffering from"/>
 <result pre="symptoms are headache, fatigue, chest tightness and diarrhea [9,24]. Previously," exact="diarrhea" post="was reported in patients suffering from MERS but not"/>
 <result pre="(LDH), Î³-glutamyl transpeptidase (Î³-GT) and Î±-hydroxybutyric dehydrogenase (Î±-HBDH) [4,24,42]. In" exact="acute" post="cases, it could lead to pneumonia, liver damage, kidney"/>
 <result pre="In acute cases, it could lead to pneumonia, liver damage," exact="kidney failure" post="and death [42,43]. Acute liver damage in patients with"/>
 <result pre="lead to pneumonia, liver damage, kidney failure and death [42,43]." exact="Acute" post="liver damage in patients with SARS or Influenza has"/>
 <result pre="SARS or Influenza has been reported in the past [24]." exact="Severe" post="cases of COVID-19 yield multiple organ dysfunction syndrome (MODS),"/>
 <result pre="past [24]. Severe cases of COVID-19 yield multiple organ dysfunction" exact="syndrome" post="(MODS), acute respiratory distress syndrome (ARDS), septic shock, acidosis"/>
 <result pre="Severe cases of COVID-19 yield multiple organ dysfunction syndrome (MODS)," exact="acute" post="respiratory distress syndrome (ARDS), septic shock, acidosis and cytokine"/>
 <result pre="cases of COVID-19 yield multiple organ dysfunction syndrome (MODS), acute" exact="respiratory" post="distress syndrome (ARDS), septic shock, acidosis and cytokine storms"/>
 <result pre="COVID-19 yield multiple organ dysfunction syndrome (MODS), acute respiratory distress" exact="syndrome" post="(ARDS), septic shock, acidosis and cytokine storms in the"/>
 <result pre="multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS)," exact="septic shock," post="acidosis and cytokine storms in the body which may"/>
 <result pre="dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), septic shock," exact="acidosis" post="and cytokine storms in the body which may lead"/>
 <result pre="which may lead to death [44,45]. COVID-19 patients also exhibited" exact="bilateral" post="focal consolidation, ground-glass opacities, lobar consolidation and diffused patchy"/>
 <result pre="may lead to death [44,45]. COVID-19 patients also exhibited bilateral" exact="focal" post="consolidation, ground-glass opacities, lobar consolidation and diffused patchy consolidation"/>
 <result pre="consolidation, ground-glass opacities, lobar consolidation and diffused patchy consolidation in" exact="chest" post="radiography [4]. The three viruses have similar zoonotic transmission"/>
 <result pre="to humans but unlike SARS and MERS, SARS-CoV-2 rarely causes" exact="runny nose" post="and gastrointestinal symptoms [43]. Several asymptomatic individuals were also"/>
 <result pre="for SARS-CoV-2. In a comprehensive study by Chinese Center for" exact="Disease" post="Control and Prevention (China CDC) involving 72,314 SARS-CoV-2 positive"/>
 <result pre="Wuhan, China were reported to be asymptomatic carriers of the" exact="disease" post="[46]. The total number of such asymptomatic cases pan"/>
 <result pre="reported to be asymptomatic carriers of the disease [46]. The" exact="total" post="number of such asymptomatic cases pan globe is unknown"/>
 <result pre="The present treatment employs two-pronged approachâ€&quot;use of antibiotics to prevent" exact="secondary" post="infections and use of available antiviral drugs to eliminate"/>
 <result pre="present treatment employs two-pronged approachâ€&quot;use of antibiotics to prevent secondary" exact="infections" post="and use of available antiviral drugs to eliminate the"/>
 <result pre="well as chloroquine, and remdesivir. Lopinavir and ritonavir, remdesivir inhibit" exact="viral" post="replication. Patients have shown positive responses to treatments with"/>
 <result pre="many more [2]. Hydroxychloroquine, an anti-malarial and anti-inflammatory drug inhibits" exact="viral" post="replication by increasing the pH of endosomes that house"/>
 <result pre="This has been used previously for leprosy, advanced non-small cell" exact="lung cancer" post="and severe gram-negative sepsis. Presently, several research groups are"/>
 <result pre="has been used previously for leprosy, advanced non-small cell lung" exact="cancer" post="and severe gram-negative sepsis. Presently, several research groups are"/>
 <result pre="the development of a non-human primate model to study SARS-CoV-2" exact="infection" post="for testing potential vaccines and antivirals. In addition to"/>
 <result pre="prove instrumental in drug and vaccine development [43]. Macaques and" exact="African" post="green monkeys have identical sequences of cell surface proteins"/>
 <result pre="cell surface proteins that may allow the entry of SARS-CoV-2." exact="African" post="Green, Rhesus and Cynomolgus Monkeys have been previously tested"/>
 <result pre="the maximum amount of serum neutralizing antibody is produced in" exact="African" post="green monkey, followed by cynomolgus and rhesus macaques against"/>
 <result pre="and rhesus macaques against SARS infection, respectively [49]. Though the" exact="infection" post="model for SARS-CoV-2 in these non-human primates shows successful"/>
 <result pre="for SARS-CoV-2 in these non-human primates shows successful replication, the" exact="African" post="green monkey appears as a better model as it"/>
 <result pre="model as it requires lower, close to natural dose for" exact="infection" post="and develops advanced respiratory disease [50]. Variation in level"/>
 <result pre="lower, close to natural dose for infection and develops advanced" exact="respiratory" post="disease [50]. Variation in level of viral replication and"/>
 <result pre="close to natural dose for infection and develops advanced respiratory" exact="disease" post="[50]. Variation in level of viral replication and subsequent"/>
 <result pre="and develops advanced respiratory disease [50]. Variation in level of" exact="viral" post="replication and subsequent clinical manifestation may be a challenge"/>
 <result pre="of these models. 2.2. Vaccine Trials and Challenges In the" exact="absence of" post="any effective antiviral treatment for SARS-CoV-2, development of an"/>
 <result pre="world. Spike protein plays a major role in receptor recognition," exact="viral" post="invasion into the cell and is also exposed to"/>
 <result pre="mRNA-1273 developed by the US National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) in partnership with Moderna. An adenovirus based"/>
 <result pre="developed by the US National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) in partnership with Moderna. An adenovirus based vaccine"/>
 <result pre="clinical trials in South Korea [52]. Indian company Serum India" exact="Limited" post="is also participating in a ChAdOx1-S vaccine development program."/>
 <result pre="Biotechnology Co., Beijing, China with funding from the Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI) is working on separate nucleic acid"/>
 <result pre="antibody-dependent enhancement. In antibody-dependent enhancement, the antibody itself facilitates the" exact="viral" post="entry into the cells via Ig Fc receptors [53,54]."/>
 <result pre="the case of veterinary vaccines against animal coronaviruses, including feline" exact="infectious" post="peritonitis virus [54]. Further, studies of animal coronaviruses have"/>
 <result pre="case of veterinary vaccines against animal coronaviruses, including feline infectious" exact="peritonitis" post="virus [54]. Further, studies of animal coronaviruses have established"/>
 <result pre="surpassed previous coronavirus outbreaks of the past in terms of" exact="total" post="deaths, number of affected individuals; though it has lower"/>
 <result pre="of total deaths, number of affected individuals; though it has" exact="lower" post="CFR (case fatality rate) [3,10,24]. Restricted and inadequate information"/>
 <result pre="the virus out pan globe. European nations didnâ€™t impose a" exact="complete" post="lockdown, hence despite having advanced healthcare services, they have"/>
 <result pre="the unavailability of a suitable animal model to study the" exact="disease" post="and pre-clinical trials [43]. In absence of any reliable"/>
 <result pre="model to study the disease and pre-clinical trials [43]. In" exact="absence of" post="any reliable treatment, identification in infected individuals and their"/>
 <result pre="contain the pandemic. Current diagnostic approaches for detection of SARS-CoV-2" exact="infections" post="are based on RT-PCR that detects the presence of"/>
 <result pre="infections are based on RT-PCR that detects the presence of" exact="viral" post="nucleic acid in the patient sample or a serological"/>
 <result pre="which detects IgG or/and IgM antibodies formed against the causative" exact="viral" post="antigens. Another serological approach relies on detecting the SARS-CoV-2"/>
 <result pre="isolated event or may it occur repeatedly? Also, is the" exact="recurrent" post="infection, reinfection or second attack of SARS-CoV-2 possible or"/>
 <result pre="the reason for reinfection lies in partial/incomplete immunity generated after" exact="primary" post="infection. Respiratory track viral infections invade primarily superficial respiratory"/>
 <result pre="for reinfection lies in partial/incomplete immunity generated after primary infection." exact="Respiratory" post="track viral infections invade primarily superficial respiratory epithelial cells."/>
 <result pre="lies in partial/incomplete immunity generated after primary infection. Respiratory track" exact="viral" post="infections invade primarily superficial respiratory epithelial cells. Probably, cells"/>
 <result pre="in partial/incomplete immunity generated after primary infection. Respiratory track viral" exact="infections" post="invade primarily superficial respiratory epithelial cells. Probably, cells containing"/>
 <result pre="after primary infection. Respiratory track viral infections invade primarily superficial" exact="respiratory" post="epithelial cells. Probably, cells containing acquired resistance are replaced"/>
 <result pre="primary infection. Respiratory track viral infections invade primarily superficial respiratory" exact="epithelial" post="cells. Probably, cells containing acquired resistance are replaced by"/>
 <result pre="infections invade primarily superficial respiratory epithelial cells. Probably, cells containing" exact="acquired" post="resistance are replaced by new sensitive cells. Also, serum"/>
 <result pre="capacity to neutralize virus particles canâ€™t easily access the superficial" exact="respiratory" post="epithelial cells. Still locally induced and secreted IgA can"/>
 <result pre="to neutralize virus particles canâ€™t easily access the superficial respiratory" exact="epithelial" post="cells. Still locally induced and secreted IgA can directly"/>
 <result pre="of discharge patients may be due to false-negative detection of" exact="residual" post="RNA fragments of dead virus fragments or patients may"/>
 <result pre="fragments or patients may not be fully recovered. But, a" exact="complete" post="picture is still awaited. Lastly, there will be no"/>
 <result pre="India), DST (Department of Biotechnology, India) for monetary support and" exact="Central" post="University of Rajasthan, India for providing infrastructure and facilities"/>
 <result pre="interest. References References 1.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 2.VelavanT.P.MeyerC.G.The COVID-19 epidemicTrop."/>
 <result pre="and receptor bindingLancet202039556557410.1016/S0140-6736(20)30251-832007145 4.WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.et al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 5.HelmyY.A.FawzyM.ElaswadA.SobiehA.KenneyS.P.ShehataA.A.The COVID-19 pandemic: A comprehensive review"/>
 <result pre="receptor bindingLancet202039556557410.1016/S0140-6736(20)30251-832007145 4.WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.et al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526910.1038/s41586-020-2008-332015508 5.HelmyY.A.FawzyM.ElaswadA.SobiehA.KenneyS.P.ShehataA.A.The COVID-19 pandemic: A comprehensive review of"/>
 <result pre="Med. Virol.20209257758310.1002/jmv.2575732162702 10.WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in ChinaJ. Am. Med. Assoc.20203231239124210.1001/jama.2020.2648 11.WHO"/>
 <result pre="2019 (COVID-19) outbreak in ChinaJ. Am. Med. Assoc.20203231239124210.1001/jama.2020.2648 11.WHO Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;85WHOGeneva, Switzerland42020 12.DuffyS.Why are RNA virus"/>
 <result pre="or SNPs of SARS-CoV-2: A point of cautionGene202075214479210.1016/j.gene.2020.14479232445924 14.PeckK.M.LauringA.S.Complexities of" exact="viral" post="mutation ratesJ. Virol.20189210.1128/JVI.01031-1729720522 15.SanjuÃ¡nR.NebotM.R.ChiricoN.ManskyL.M.BelshawR.Viral mutation ratesJ. Virol.2010849733974810.1128/JVI.00694-1020660197 16.CuiJ.LiF.ShiZ.L.Origin and"/>
 <result pre="bat coronavirus closely related to the direct progenitor of severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.2016903253325610.1128/JVI.02582-15 19.HuB.ZengL.P.YangX.L.GeX.Y.ZhangW.LiB.XieJ.Z.ShenX.R.ZhangY.Z.WangN.et al.Discovery of a rich"/>
 <result pre="coronavirus closely related to the direct progenitor of severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.2016903253325610.1128/JVI.02582-15 19.HuB.ZengL.P.YangX.L.GeX.Y.ZhangW.LiB.XieJ.Z.ShenX.R.ZhangY.Z.WangN.et al.Discovery of a rich gene"/>
 <result pre="closely related to the direct progenitor of severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.2016903253325610.1128/JVI.02582-15 19.HuB.ZengL.P.YangX.L.GeX.Y.ZhangW.LiB.XieJ.Z.ShenX.R.ZhangY.Z.WangN.et al.Discovery of a rich gene pool"/>
 <result pre="to novel coronavirus-Old lessons and new lessonsEpidemiol. Infect.20201410.1017/S095026882000025432019614 25.WHO Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;57WHOGeneva, Switzerland2020Volume 49e99e10010.3928/19382359-20200219-01 26.UddinM.MustafaF.RizviT.A.LoneyT.SuwaidiH.A.MarzouqiA.A.EldinA.K.AlsabeehaN.AdrianT.E.SARS-CoV-2 / COVID-19:"/>
 <result pre="Disease 2019 (COVID-19) Situation Reportâ€&quot;57WHOGeneva, Switzerland2020Volume 49e99e10010.3928/19382359-20200219-01 26.UddinM.MustafaF.RizviT.A.LoneyT.SuwaidiH.A.MarzouqiA.A.EldinA.K.AlsabeehaN.AdrianT.E.SARS-CoV-2 / COVID-19:" exact="Viral" post="genomics, epidemiology, vaccines, and therapeutic interventionsPreprints202011710.20944/preprints202004.0005.v1 27.Van DoremalenN.BushmakerT.MorrisD.H.HolbrookM.G.GambleA.WilliamsonB.N.TaminA.HarcourtJ.L.ThornburgN.J.GerberS.I.et al.Aerosol"/>
 <result pre="difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2)" exact="infection" post="between travelers to Hubei and non-travelers: The need of"/>
 <result pre="quarantine periodInfect. Control. Hosp. Epidemiol.202010.1017/ice.2020.81 30.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.C.et al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.202011310.1056/NEJMoa2002032 31.LiQ.GuanX.WuP.WangX.ZhouL.TongY.RenR.LeungK.S.M.LauE.H.Y.WongJ.Y.et al.Early transmission"/>
 <result pre="COVID-19 outbreak in ChinaJ. Travel Med.202027taaa03710.1093/jtm/taaa03732181488 33.XieZ.Pay attention to SARS-CoV-2" exact="infection" post="in childrenPediatr. Investig.202041410.1002/ped4.12178 34.YuanB.ChenY.ZhangK.WangC.Recurrence of positive SARS-CoV-2 Viral RNA"/>
 <result pre="to SARS-CoV-2 infection in childrenPediatr. Investig.202041410.1002/ped4.12178 34.YuanB.ChenY.ZhangK.WangC.Recurrence of positive SARS-CoV-2" exact="Viral" post="RNA in recovered COVID-19 patients during medical isolation observationNat."/>
 <result pre="online: https://www.indiatoday.in/diu/story/coronavirus-india-young-patients-age-groups-covid19-1662698-2020-04-03(accessed on 28 May 2020) 42.WangS.GuoL.ChenL.LiuW.CaoY.ZhangJ.FengL.A case report of" exact="neonatal" post="COVID-19 infection in ChinaClin. Infect. Dis.2020ciaa22510.1093/cid/ciaa22532161941 43.RothanH.A.ByrareddyS.N.The epidemiology and"/>
 <result pre="on 28 May 2020) 42.WangS.GuoL.ChenL.LiuW.CaoY.ZhangJ.FengL.A case report of neonatal COVID-19" exact="infection" post="in ChinaClin. Infect. Dis.2020ciaa22510.1093/cid/ciaa22532161941 43.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of"/>
 <result pre="in ChinaClin. Infect. Dis.2020ciaa22510.1093/cid/ciaa22532161941 43.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.202010910243310.1016/j.jaut.2020.10243332113704 44.WangL.S.WangY.R.YeD.W.LiuQ.Q.A review of the 2019 Novel"/>
 <result pre="Agents202010594810.1016/j.ijantimicag.2020.10594832201353 45.ZhaoD.YaoF.WangL.ZhengL.GaoY.YeJ.GuoF.ZhaoH.GaoR.A comparative study on the clinical features of COVID-19" exact="pneumonia" post="to other pneumoniasClin. Infect. Dis.202010.1093/cid/ciaa247 46.NishiuraH.KobayashiT.SuzukiA.JungS.-M.HayashiK.KinoshitaR.YangY.YuanB.AkhmetzhanovA.R.LintonN.M.et al.Estimation of the"/>
 <result pre="Dis.202010.1093/cid/ciaa247 46.NishiuraH.KobayashiT.SuzukiA.JungS.-M.HayashiK.KinoshitaR.YangY.YuanB.AkhmetzhanovA.R.LintonN.M.et al.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19)Int. J. Infect. Dis.202010.1016/j.ijid.2020.03.020 47.PeeriN.C.ShresthaN.RahmanS.TanZ.BibiS.BaghbanzadehM.The SARS, MERS and novel"/>
 <result pre="Dis.2020810166310.1016/j.tmaid.2020.10166332289548 49.McAuliffeJ.VogelL.RobertsA.FahleG.FischerS.ShiehW.J.ButlerE.ZakiS.St. ClaireM.MurphyB.et al.Replication of SARS coronavirus administered into the" exact="respiratory" post="tract of African Green, rhesus and cynomolgus monkeysVirology200433081510.1016/j.virol.2004.09.03015527829 50.WoolseyC.B.BorisevichV.PrasadA.N.AgansK.N.DeerD.J.DobiasN.S.HeymannJ.C.FosterS.L.LevineC.B.MedinaL.et"/>
 <result pre="al.Replication of SARS coronavirus administered into the respiratory tract of" exact="African" post="Green, rhesus and cynomolgus monkeysVirology200433081510.1016/j.virol.2004.09.03015527829 50.WoolseyC.B.BorisevichV.PrasadA.N.AgansK.N.DeerD.J.DobiasN.S.HeymannJ.C.FosterS.L.LevineC.B.MedinaL.et al.Establishment of an"/>
 <result pre="African Green, rhesus and cynomolgus monkeysVirology200433081510.1016/j.virol.2004.09.03015527829 50.WoolseyC.B.BorisevichV.PrasadA.N.AgansK.N.DeerD.J.DobiasN.S.HeymannJ.C.FosterS.L.LevineC.B.MedinaL.et al.Establishment of an" exact="African" post="green monkey model for COVID-19bioRxiv2020bioRxiv: 2020.05.17.10028910.1101/2020.05.17.100289 51.ChenW.-H.StrychU.HotezP.J.BottazziM.E.The SARS-CoV-2 Vaccine"/>
 <result pre="human coronavirus (SARS-CoV-2): A lesson from animal coronavirusesVet. Microbiol.202024410869310.1016/j.vetmic.2020.10869332402329 56.ChangT.W.Recurrent" exact="viral infection" post="(reinfection)N. Engl. J. Med.197128476577310.1056/NEJM1971040828414064323312 Figure 1 (A) Percentage distribution"/>
 <result pre="coronavirus (SARS-CoV-2): A lesson from animal coronavirusesVet. Microbiol.202024410869310.1016/j.vetmic.2020.10869332402329 56.ChangT.W.Recurrent viral" exact="infection" post="(reinfection)N. Engl. J. Med.197128476577310.1056/NEJM1971040828414064323312 Figure 1 (A) Percentage distribution"/>
 <result pre="and active cases in worst-hit countries in the world. (B)" exact="Infection" post="growth rate of some of the worst infected countries"/>
 <result pre="Candidate Vaccine in Clinical Trial Developer Current Stage Non Replicating" exact="Viral" post="Vector ChAdOx1-S University of Oxford/AstraZeneca, Cambridge, U.K. /Serum Institute"/>
 <result pre="Institute of India Phase2b/3 2020-001228-32 Phase 1/2 2020-001072-15 Non Replicating" exact="Viral" post="Vector Adenovirus Type 5 Vector CanSino Biological Inc., China/Beijing"/>
 <result pre="Phase2b/3 2020-001228-32 Phase 1/2 2020-001072-15 Non Replicating Viral Vector Adenovirus" exact="Type 5" post="Vector CanSino Biological Inc., China/Beijing Institute of Biotechnology, China"/>
 <result pre="encapsulated mRNA Moderna Inc., USA/ National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), USA Phase 2 (IND submitted) Phase 1"/>
 <result pre="mRNA Moderna Inc., USA/ National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), USA Phase 2 (IND submitted) Phase 1 NCT04283461"/>
 <result pre="+ Alum Sinovac Biotech Ltd., China Phase 1/2 NCT04383574 NCT04352608" exact="Protein" post="Subunit Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted"/>
</results>
